A perspective from the University of Basel challenges the dominant therapeutic paradigm for sarcopenia — the progressive loss of muscle mass and strength affecting roughly 10-16% of adults over 65. The authors argue that decades of interventions targeting anabolic/catabolic signaling pathways within muscle fibers themselves may be fundamentally misdirected if the primary drivers of age-related wasting originate upstream in motor neurons, muscle stem cells, or fibro-adipogenic progenitors. Emerging cell-targeting technologies, including AAV capsid delivery systems and antibody-directed therapeutics, now make precision interventions at these alternative cellular origins genuinely feasible.
This reframing carries real clinical weight. The field has long chased myostatin inhibition, IGF-1 pathways, and mTOR signaling within muscle fibers — producing largely disappointing trial results in humans despite compelling animal data. The growing recognition that denervation-driven fiber atrophy may precede intrinsic muscle deterioration shifts priority toward neuroprotection and neuromuscular junction maintenance, an underexplored frontier. The acknowledgment of individual heterogeneity — sex, genetics, comorbidities, activity — is equally important, suggesting one-size therapeutic strategies are unlikely to succeed. The paper is a review/perspective rather than primary data, which limits its immediate evidentiary weight, but its synthesis of mechanistic complexity serves as a useful corrective to an overly reductionist research agenda. For practicing clinicians, the durable message remains: resistance training and protein adequacy address multiple mechanisms simultaneously and remain the most validated multi-target intervention available today.
